A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with severe depression, the FDA says. Here's what that means.
NeuroStar is committed to advancing the body of scientific research and elevating mental health treatment through robust research and data-driven innovation,” stated Keith J. Sullivan, President and ...
People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
The move expands access to the novel mental health treatment, which has shown rapid symptom improvement for the past few years now.
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...
The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...
Interesting Engineering on MSN8d
US approves first nasal spray for major depressive disorder, PTSD conditionsJohnson & Johnson has announced a major breakthrough in mental health treatment. The Food and Drug Administration (FDA) has approved Spravato, a novel nasal spray, for the standalone treatment of ...
A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug ...
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback